Chantix (varenicline) was developed as a smoking cessation drug, but the same active ingredient has found a second FDA-approved life as a treatment for dry eye disease. Beyond that, researchers have been studying varenicline for alcohol use disorder, certain neurological conditions, and cognitive problems in psychiatric disorders, with some promising early results.
Dry Eye Disease: A Second FDA Approval
The most concrete non-smoking use of varenicline is a nasal spray called Tyrvaya, FDA-approved for treating the signs and symptoms of dry eye disease. Tyrvaya contains the same active compound as Chantix but delivers it through the nose rather than as a pill. The spray works by activating nerve pathways that stimulate your eyes’ natural tear production, a completely different mechanism from artificial tears or lubricating drops that simply add moisture to the eye’s surface.
This isn’t an off-label use or experimental treatment. Tyrvaya is a fully approved product with its own prescribing information, and eye care specialists prescribe it regularly. If you’ve been struggling with dry eyes and standard drops haven’t helped, this is worth discussing with your eye doctor.
Reducing Alcohol Consumption
Varenicline’s effect on alcohol use is the most researched off-label application, and the science behind it is straightforward. The drug partially activates the same brain receptors that alcohol stimulates to release dopamine, the chemical tied to reward and pleasure. The theory is that by keeping dopamine levels slightly elevated, varenicline reduces the brain’s drive to seek alcohol for that same effect.
A randomized, double-blind trial published in The Lancet Regional Health tested this in people with alcohol use disorder over 12 weeks. Participants taking varenicline alone (at the same 1 mg twice-daily dose used for smoking) showed meaningful reductions in both a blood marker of alcohol consumption and in the percentage of heavy drinking days compared to placebo. The effect sizes were moderate, and when varenicline was combined with bupropion (another drug that boosts dopamine activity), the reductions were even larger. The combination also reduced alcohol cravings and increased the number of days participants stayed completely sober.
This is still considered off-label. No regulatory agency has approved varenicline specifically for alcohol use disorder, so prescribing it for this purpose is at a doctor’s discretion. But the evidence is building, and some addiction specialists already use it this way, particularly for patients who both smoke and drink heavily.
Balance and Movement in Spinocerebellar Ataxia
Spinocerebellar ataxia type 3 is a genetic condition that progressively damages the part of the brain controlling coordination, leading to worsening problems with walking, balance, and fine motor skills. There’s no approved treatment that slows or reverses it. Researchers tested varenicline because it activates a specific type of nicotinic receptor in the brain thought to play a role in motor coordination.
In a randomized, placebo-controlled trial published in Neurology, patients who took varenicline for eight weeks showed statistically significant improvements in gait, stance, walking speed (measured by a timed 25-foot walk), and the ability to perform rapid alternating hand movements. Depression scores also improved. The overall ataxia severity score trended toward improvement but narrowly missed statistical significance.
These results are encouraging for a disease with very few treatment options, but the trial was small and short. Varenicline is not an established therapy for ataxia, and the improvements, while real, were modest. Still, for patients and families dealing with this condition, it represents one of the few pharmacological leads that has shown any benefit in a controlled trial.
Cognitive Function in Schizophrenia
People with schizophrenia often experience significant cognitive difficulties: trouble with working memory, attention, and processing speed. These problems persist even when psychotic symptoms are well controlled with antipsychotic medications, and they have a major impact on daily functioning. Researchers hypothesized that because varenicline activates nicotinic receptors known to influence attention and memory in animal studies, it might help fill this treatment gap.
Clinical trials have tested varenicline as an add-on to antipsychotic medications, using the standard titration schedule (starting low and increasing to 1 mg twice daily over the first week). The rationale is solid, and the trials have been rigorously designed with double-blind, placebo-controlled protocols. However, results from these studies have been mixed, and varenicline has not become a standard cognitive treatment in schizophrenia. It remains a research interest rather than a clinical recommendation.
What About Weight Loss?
If you searched this topic hoping varenicline might help with weight management, the evidence doesn’t support that. Some studies have looked at whether varenicline prevents the weight gain people commonly experience after quitting smoking, and while there may be minor short-term effects, research has found no long-term weight gain prevention benefit. No studies have demonstrated meaningful weight loss in people who weren’t using it for smoking cessation. This appears to be a dead end rather than a promising off-label use.
Why One Drug Has So Many Potential Uses
Varenicline’s versatility comes down to its target: nicotinic acetylcholine receptors. These receptors aren’t just involved in nicotine addiction. They’re found throughout the brain and nervous system, playing roles in dopamine release (relevant to alcohol and reward), motor coordination (relevant to ataxia), tear production (relevant to dry eye), and cognitive processes like attention and memory. A drug that activates these receptors, even partially, can potentially influence all of these systems.
The important distinction is between what’s proven and what’s promising. Dry eye treatment with Tyrvaya nasal spray is fully approved and available. Alcohol use disorder has strong clinical trial evidence but no formal approval. Ataxia and cognitive enhancement have intriguing early data but remain experimental. If you’re considering varenicline for anything other than smoking cessation or dry eye, that conversation needs to happen with a doctor who can weigh the evidence against your specific situation.